clinical trial · NCT07177937
A Study of DXC014 in Patients With Advanced Solid Tumors.
Hangzhou DAC Biotechnology Co., Ltd.·phase1·recruiting·n = 150
Small Cell Lung CancerMelanomaProstate CancerOther Advanced Solid TumorsDXC014
brief summary
This is a phase I, open-label, first-in-human clinical study designed to evaluate the safety, tolerability, MTD, DLT, RP2D, the PK characteristics, preliminary anti-tumor activity, the immunogenicity of DXC014 in patients with Advanced Solid Tumors.
started
Mar 3, 2026
primary completion
Oct 20, 2030
completion
Oct 20, 2030
last updated
Apr 24, 2026
official title
An Open-Label, Multicenter, First-in-Human, Dose-Escalation and Expansion Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of DXC014 for Injection in Patients With Advanced Solid Tumors.
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol